Welcome to Drug and Alcohol Treatment
| ||
Drug Treatment Fungal Infections Article
This is a selection made from among articles on Drug Treatment Fungal Infections. For a permanent link to this article, or to bookmark it for future reading, click here.
from:
Alcohol And Drug Rehab Must Be Covered By Pennsylvania Insurance
By Rod MacTaggart
A Pennsylvania Commonwealth Court has ruled that HMOs and group insurance companies must cover drug and alcohol treatment costs for policy holders referred to detoxification, rehabilitation and outpatient programs by a doctor or psychologist. The unanimous decision will help about 15,000 state residents with private insurance who need help through drug detox and drug rehab each year.
A 1989 state law requires insurance companies to cover drug and alcohol detox and rehab services. Aetna, Independence Blue Cross, the Insurance Federation of Pennsylvania and other managed-care groups sued the state’s Insurance Department, saying that they should be allowed to review drug and alcohol treatment referrals to make sure that treatment is appropriate. But the court sided with the Insurance Department's interpretation that treatment would be covered as long as a doctor or psychologist prescribed the alcohol or drug rehab program.
“It's a really important decision,” said Deborah Beck, president of the Drug and Alcohol Service Providers Organization of Pennsylvania. “Somebody at the end of an 800 number in another state should never be making these decisions.”
The insurance industry could appeal to the state Supreme Court and argue that state law allows insurers to review treatment in other health care areas before paying for care, and that it’s reasonable that alcohol and drug detox and drug rehab programs should be treated the same way. The insurance industry’s reviews of alcohol and drug rehab referrals would be conducted by physicians and psychologists, an Insurance Federation of Pennsylvania spokesman said, adding that when you don't have scrutiny over treatment patterns, you get increased health care costs.
However, doctors and psychologists who review cases for the insurance companies are paid by the insurance companies. Although this fact was not openly considered as part of the court’s ruling, the fact remains that reviewers’ decisions could tend to favor their employers – the HMOs and insurance companies – rather than the addicts, whos own treatment professionals have already determined that they need alcohol and drug detox and drug rehab programs.
Battling with HMOs and group insurers over desperately needed coverage is nothing new to Americans. The issue has been widely popularized in several books and movies that detailed the horrors resulting from the insurance industry’s penchant to favor their bottom line ahead of patient health.
According to Beck, slowing down the availability of alcohol and drug rehab through a complicated approvals process places addicts at risk. They might “disappear and die,” she said, adding that the court ruling upholds a “life-saving” law.
After nearly two decades on the books, the Pennsylvania law may finally have the chance to accomplish its intentions – to get people suffering from substance abuse and addictions into an alcohol or drug rehab program as quickly as possible.
Rod is a freelance writer who contributes articles on health
contact: info@drugrehabreferral.com
http://www.drugrehabreferral.com/content/drug_rehab
Article Source: http://EzineArticles.com/?expert=Rod_MacTaggart
http://EzineArticles.com/?Alcohol-And-Drug-Rehab-Must-Be-Covered-By-Pennsylvania-Insurance&id=677099
Drug Treatment Fungal Infections Specific links
Drug Treatment Fungal Infections News
Basilea participates in public-private collaboration to tackle antibiotic resistance
Basel, Switzerland, May 25, 2012 - Basilea Pharmaceutica Ltd. welcomes the launch in Europe of a pioneering approach to antibiotic research that will see pharmaceutical and biotechnology companies working ...
Read more...C3 Jian Obtains FDA Acceptance of Investigational New Drug Application
LOS ANGELES -- C3 Jian, Inc., a private company focused on providing improved oral healthcare, announced today that its Investigational New Drug Application (IND) for its novel drug, C16G2, has been accepted ...
Read more...Novartis Drug Afinitor® Approved By FDA As First Medication To Treat Patients With Non-Cancerous Kidney Tumors ...
Novartis Pharmaceuticals Corporation ("Novartis") announced today that the US Food and Drug Administration (FDA) approved Afinitor® (everolimus) tablets* for the treatment of adult patients with kidney tumors known as renal angiomyolipomas and tuberous sclerosis complex (TSC), who do not require immediate surgery(2).
Read more...NovaDigm Therapeutics Presents Positive Safety and Immunogenicity Data in a Second Phase 1 Study for NDV-3 Vaccine
NovaDigm Therapeutics, a company developing innovative vaccines for fungal and bacterial infections, today announced the presentation of positive data for its NDV-3 vaccine program in a second Phase 1 study.
Read more...MicuRx Pharmaceuticals Announces Issuance Of U.S. Patent For Its Next-Generation Antibacterial Agent
HAYWARD, Calif., and SHANGHAI, May 23, 2012 /PRNewswire/ -- MicuRx Pharmaceuticals, Inc., a privately-held biopharmaceutical company developing next-generation antibiotics, today announced that the U.S. ...
Read more...Sunovion Announces Upcoming Availability of ZETONNA™ (ciclesonide) Nasal Aerosol, a Non-Aqueous, Dry Nasal Aerosol ...
Sunovion Pharmaceuticals Inc. today announced the upcoming availability of ZETONNA™ Nasal Aerosol, 74 mcg once-daily, for the treatment of allergic rhinitis , also known as hay fever or nasal allergies.
Read more...Innovotech Reports First Quarter 2012 Financial Results
EDMONTON, ALBERTA-- - Innovotech Inc. announced its audited financial and operational results for the quarter ended March 31, 2012.Highlights:--  Innovotech receives initial purchase orders for Human and Veterinary    InnovoSCEPT products --  Encouraging interim results in one of the two blinded study groups from    the clinical trial at the Hospital for Sick Children --  Launched aggressive ...
Read more...Significant Improvement In Disability Scores With Alemtuzumab
Genzyme presented additional data at the 64th Annual Meeting of the American Academy of Neurology from its Phase II CARE-MS II trial, which demonstrated that the Expanded Disability Status Scale (EDSS), i.e. a standard assessment of physical disability progression showed a considerably slower accumulation of disability in patients with multiple sclerosis (MS) who were treated with alemtuzumab ...
Read more...Dermatological Drugs: World Market Prospects 2012-2022
NEW YORK, May 2, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue: Dermatological Drugs: World Market Prospects 2012-2022 http://www.reportlinker.com/p0788690/Dermatological-Drugs-World-Market-Prospects-2012-2022.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_MedicationReport ...
Read more...Tips from the journals of the American Society for Microbiology
( American Society for Microbiology ) In this month's issue: "Genes Culled From Desert Soils Suggest Potential Medical Resource"; "Garlic Constituent Blocks Biofilm Formation, Could Benefit CF Patients and Others"; "Experimental Vaccine Elicits Robust Response Against Both HIV and Tuberculosis"; and "Antibiotics Boost Risk of Infection with Antifungal-Resistant Candida."
Read more...